The FDA recently approved the drug Alyftrek for cystic fibrosis patients (6+) with specific mutations. The trial, led by Jordana Hoppe, MD, of @cumedicalschool.bsky.social, took place at our pediatric Clinical Translational Research Center!
@cupediatrics.bsky.social
@cumedicalschool.bsky.social